Immukine (Recombinant Human Interferon Gamma 1b)

Interferon gamma‑1b binds to interferon‑gamma receptors on immune cells, activating the JAK‑STAT pathway. This signaling increases expression of genes that boost antigen presentation, enhance macrophage microbicidal activity, promote Th1‑type T‑cell responses, and stimulate osteoclast differentiation, thereby correcting the underlying immune or bone‑remodeling defects.

The dose of Immukine is individualized and determined by the prescribing physician based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals follow approved dosing guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for interferon gamma‑1b during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Immukine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternative to interferon gamma‑1b is interferon alfa, which primarily exerts antiviral effects and is used for different indications such as hepatitis C. Interferon gamma‑1b uniquely enhances macrophage activation and Th1 immunity, making it the preferred choice for conditions like chronic granulomatous disease, whereas interferon alfa does not address the underlying phagocyte defect.

Immukine must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, use validated cold‑chain containers to maintain the temperature range throughout shipment.

Immukine is supplied as a sterile solution for subcutaneous injection. The injection is typically given by a healthcare professional in a clinical setting. The injection site is rotated to minimize local irritation, and patients are observed for any immediate adverse reactions following administration.

Serious risks include hepatic dysfunction (elevated liver enzymes or hepatitis), hematologic abnormalities such as anemia or leukopenia, severe allergic reactions including anaphylaxis, and the development of autoimmune phenomena. Patients should be monitored regularly for these events, and therapy should be discontinued if any serious reaction occurs.

Immukine is contraindicated in individuals with known hypersensitivity to interferon gamma‑1b or any excipients in the formulation. It should also be avoided in patients with active, uncontrolled autoimmune diseases unless the treating physician determines that the benefits outweigh the risks.